Filing Flows › Gilead Sciences (GILD) › Trodelvy revenue
Gilead Sciences (GILD) Trodelvy revenue by quarter
Gilead Sciences' Trodelvy revenue was $506M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $293M (Q1 2025) to $506M (Q3 2026).
| Quarter | Trodelvy revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $506M | +11% | +42% |
| Q2 2026 | $457M | +14% | +26% |
| Q1 2026 | $402M | +5% | +37% |
| Q4 2025 | $384M | +8% | — |
| Q3 2025 | $357M | -2% | — |
| Q2 2025 | $364M | +24% | — |
| Q1 2025 | $293M | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' Trodelvy revenue?
Gilead Sciences' Trodelvy revenue was $506M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Gilead Sciences' Trodelvy revenue changed?
Over the last 7 quarters it ranged from $293M (Q1 2025) to $506M (Q3 2026).